Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study
Bernardo Dell’Osso, Chiara Arici, Cristina Dobrea, Giulia Camuri, Beatrice Benatti, A Carlo AltamuraUniversity of Milan, Department of Psychiatry, Fondazione IRCSS Ca’ Granda, Ospedale Maggiore Policlinico, Milano, ItalyBackground: Escitalopram is a selective serotonin re...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a8b909c40d56453eadc60169f33f3b5a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a8b909c40d56453eadc60169f33f3b5a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a8b909c40d56453eadc60169f33f3b5a2021-12-02T05:47:22ZEscitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study1176-63281178-2021https://doaj.org/article/a8b909c40d56453eadc60169f33f3b5a2013-02-01T00:00:00Zhttp://www.dovepress.com/escitalopram-tolerability-as-mono--versus-augmentative-therapy-in-pati-a12165https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Bernardo Dell’Osso, Chiara Arici, Cristina Dobrea, Giulia Camuri, Beatrice Benatti, A Carlo AltamuraUniversity of Milan, Department of Psychiatry, Fondazione IRCSS Ca’ Granda, Ospedale Maggiore Policlinico, Milano, ItalyBackground: Escitalopram is a selective serotonin reuptake inhibitor, widely used in the treatment of affective disorders. The purpose of this study was to examine its safety and tolerability, as mono- versus augmentative therapy, in a group of patients with affective disorders.Materials and methods: The sample consisted of 131 patients suffering from different affective disorders, including major depressive disorder, bipolar disorder, and generalized anxiety disorder, who received escitalopram for at least 4 weeks. Data were analyzed on the basis of mono- versus augmentative therapy, as well as age, gender, mean daily dosage, and patterns of combination therapy.Results: Sixty-seven (51.1%) patients were treated with monotherapy (mean dose of 11.76 mg/day) and 64 (48.9%) with augmentative escitalopram (mean dose of 12.81 mg/day). The mean duration of escitalopram treatment was 14 months. The most frequently combined compounds were: other antidepressants (36.5%), mood stabilizers (33.4%), and atypical antipsychotics (30.1%). Side effects were reported in 5.3% of the total sample and the most common were insomnia (2.3%), nausea (2.3%), and dizziness (0.8%). No significant difference, in terms of tolerability, in mono- versus augmentative therapy groups was found. In addition, neither age nor gender was significantly correlated with a greater presence of side effects. Finally, no significant correlation between dosage and side effects was observed.Conclusion: Over a 14-month observation period, escitalopram, either as monotherapy or an augmentative treatment, was found to be well tolerated in a large sample of patients with affective disorders, with an overall low rate of side effects.Keywords: affective disorders, escitalopram, tolerability, monotherapy, augmentative therapyDell'Osso BArici CDobrea CCamuri GBenatti BAltamura ACDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 205-209 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Dell'Osso B Arici C Dobrea C Camuri G Benatti B Altamura AC Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study |
| description |
Bernardo Dell’Osso, Chiara Arici, Cristina Dobrea, Giulia Camuri, Beatrice Benatti, A Carlo AltamuraUniversity of Milan, Department of Psychiatry, Fondazione IRCSS Ca’ Granda, Ospedale Maggiore Policlinico, Milano, ItalyBackground: Escitalopram is a selective serotonin reuptake inhibitor, widely used in the treatment of affective disorders. The purpose of this study was to examine its safety and tolerability, as mono- versus augmentative therapy, in a group of patients with affective disorders.Materials and methods: The sample consisted of 131 patients suffering from different affective disorders, including major depressive disorder, bipolar disorder, and generalized anxiety disorder, who received escitalopram for at least 4 weeks. Data were analyzed on the basis of mono- versus augmentative therapy, as well as age, gender, mean daily dosage, and patterns of combination therapy.Results: Sixty-seven (51.1%) patients were treated with monotherapy (mean dose of 11.76 mg/day) and 64 (48.9%) with augmentative escitalopram (mean dose of 12.81 mg/day). The mean duration of escitalopram treatment was 14 months. The most frequently combined compounds were: other antidepressants (36.5%), mood stabilizers (33.4%), and atypical antipsychotics (30.1%). Side effects were reported in 5.3% of the total sample and the most common were insomnia (2.3%), nausea (2.3%), and dizziness (0.8%). No significant difference, in terms of tolerability, in mono- versus augmentative therapy groups was found. In addition, neither age nor gender was significantly correlated with a greater presence of side effects. Finally, no significant correlation between dosage and side effects was observed.Conclusion: Over a 14-month observation period, escitalopram, either as monotherapy or an augmentative treatment, was found to be well tolerated in a large sample of patients with affective disorders, with an overall low rate of side effects.Keywords: affective disorders, escitalopram, tolerability, monotherapy, augmentative therapy |
| format |
article |
| author |
Dell'Osso B Arici C Dobrea C Camuri G Benatti B Altamura AC |
| author_facet |
Dell'Osso B Arici C Dobrea C Camuri G Benatti B Altamura AC |
| author_sort |
Dell'Osso B |
| title |
Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study |
| title_short |
Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study |
| title_full |
Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study |
| title_fullStr |
Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study |
| title_full_unstemmed |
Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study |
| title_sort |
escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study |
| publisher |
Dove Medical Press |
| publishDate |
2013 |
| url |
https://doaj.org/article/a8b909c40d56453eadc60169f33f3b5a |
| work_keys_str_mv |
AT dellamp39ossob escitalopramtolerabilityasmonoversusaugmentativetherapyinpatientswithaffectivedisordersanaturalisticstudy AT aricic escitalopramtolerabilityasmonoversusaugmentativetherapyinpatientswithaffectivedisordersanaturalisticstudy AT dobreac escitalopramtolerabilityasmonoversusaugmentativetherapyinpatientswithaffectivedisordersanaturalisticstudy AT camurig escitalopramtolerabilityasmonoversusaugmentativetherapyinpatientswithaffectivedisordersanaturalisticstudy AT benattib escitalopramtolerabilityasmonoversusaugmentativetherapyinpatientswithaffectivedisordersanaturalisticstudy AT altamuraac escitalopramtolerabilityasmonoversusaugmentativetherapyinpatientswithaffectivedisordersanaturalisticstudy |
| _version_ |
1718400250495893504 |